Immatics N.V. Ordinary Shares - IMTX STOCK NEWS

Immatics reported promising updates on its ACTengine® IMA200 clinical trials, revealing anti-tumor activity in heavily pre-treated patients. The first quarter of 2021 showed a revenue of €7.4 million, a slight increase from €7.0 million in Q1 2020. However, R&D expenses surged to €23.0 million, up from €12.2 million, contributing to a net loss of €21.6 million. As of March 31, 2021, Immatics maintained a solid cash position of €216.7 million, ensuring operational funding into 2023. The next data update for ACTengine® is expected in H2 2021.

Immatics announced positive preclinical results for its second TCR Bispecific program, IMA402, demonstrating tumor cell killing in vitro and complete regression of established tumors in an in vivo model. Targeting the PRAME peptide, IMA402 showed anti-tumor activity against PRAME-positive cancers, indicating a broad potential patient population. The clinical lead candidate has been selected and GMP manufacturing activities initiated, positioning IMA402 for submission towards IND development.

Immatics N.V. (NASDAQ: IMTX) provided a Phase 1a data update on its ACTengine® programs, reporting positive anti-tumor activity in heavily pre-treated solid cancer patients. As of December 31, 2020, the company had cash and equivalents of €232 million ($285 million), ensuring funding into 2023. Revenue for 2020 increased to €31.3 million ($38.4 million), while R&D expenses rose significantly to €67.1 million ($82.3 million). The net loss for 2020 was €229.6 million ($281.7 million), largely due to a non-cash expense tied to the ARYA merger. Additional data updates on trials are expected in H2 2021.

Immatics N.V. (NASDAQ: IMTX) announced promising early results from its ongoing Phase 1 clinical trials for engineered T cell therapies targeting solid tumors. Anti-tumor activity was observed in 9 out of 10 evaluable patients, with tumor shrinkage noted in 8 patients and one confirmed partial response. Adverse events were transient and manageable, with no major safety issues. The trials utilized low initial doses of the ACTengine® product candidates IMA201, IMA202, and IMA203. CEO Harpreet Singh highlighted the unexpected anti-tumor activity given the heavily pre-treated patient population.

Immatics N.V. (NASDAQ: IMTX) reported significant progress in its ACTengine® IMA200 clinical trial series, with seven sites in operation and initial data expected in Q1 2021. The partnership with UTHealth extends cell therapy manufacturing until 2024, enhancing operational capacity. Financially, the company holds €259.3 million ($303.6 million) in cash as of September 30, 2020. Revenue reached €7.8 million ($9.1 million) for Q3 2020, up from €5.1 million ($6.0 million) in 2019. However, a net loss of €177.1 million ($207.3 million) reflects a significant one-time expense related to the ARYA merger.

Immatics N.V. (NASDAQ: IMTX) announced promising Phase I results from its ACTolog® program, demonstrating the feasibility and tolerability of a personalized multi-target T cell therapy for cancer. The study involved 14 patients with relapsed/refractory solid tumors, highlighting a target positivity rate of 90% and significant T cell persistence. Notably, three patients exhibited long-term disease stabilization. The results suggest further evaluation of multi-target adoptive cell therapy using potent T cell receptors, especially targeting COL6A3 exon 6 as a valuable tumor target.

Immatics N.V. (IMTX) announced preclinical success for its first TCR Bispecific program, IMA401, achieving complete remissions of human tumors in xenograft mouse models. The IMA401 target has over 5-fold higher peptide levels than traditional targets, enhancing its efficacy. Favorable pharmacokinetic properties and a significant therapeutic window were also noted. The company plans to submit an IND application for IMA401 by the end of 2021, positioning it for potential clinical development.

Immatics N.V. (NASDAQ: IMTX) has appointed Arnd Christ as its new Chief Financial Officer (CFO), effective October 1, 2020. He replaces Thomas Ulmer, who is leaving for new opportunities. Arnd Christ, formerly CFO at InflaRx, brings nearly two decades of experience in managing financial operations within public biotech companies. CEO Harpreet Singh highlighted Christ's extensive background in corporate transactions and his strategic leadership as key to advancing Immatics' objectives in T cell receptor-based therapeutics. Christ expresses excitement about contributing to the company’s promising pipeline.

On September 15, 2020, Immatics N.V. (NASDAQ: IMTX) appointed Eliot Forster, PhD, to its Board of Directors. Forster, currently CEO at F-star Therapeutics and Non-Executive Chairman of Avacta plc, brings extensive leadership experience in immuno-oncology. His addition is expected to enhance Immatics' strategic direction as it advances its T cell receptor (TCR)-based therapeutics. The company's Chairman, Peter Chambré, noted that Forster's experience will aid in achieving clinical milestones and expanding its cancer treatment pipeline.